TAK Currently At Short EntryTAK showing large wick rejection on weekly. Reward/risk here is 3.0 with trade as pictured and entries scattered across the red zone.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.15 EUR
882.16 M EUR
26.11 B EUR
1.54 B
About TAKEDA PHARMACEUTICAL CO LTD
Sector
CEO
Christophe Weber
Headquarters
Osaka
Website
Founded
1781
ISIN
JP3463000004
FIGI
BBG010BGT4S0
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
TAK : SQUARE ROOT / POSITION TRADEThe Square Root set-up appears in large cap stocks that underwent capitulation. Because large caps are heavily traded, the high liquidity reduces sharp movements. This set-up is best for position trading and usually is a sweet spot for establishing a core position on a stock that potentially has lo
Big Bull Run, 30+ short term, 50+ long term
30 within month
50+ within year
Takeda has made significant moves in the development of it's global pipeline. From the MASSIVE moves with various COVID vaccine manufacturers, to acquiring smaller Immunology biotech startups, and increase in Boston research sphere. I am the most bullish on Takeda
4502 (TSE) - Be CarefullGreetings
Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, do not be hesitant to send us message (inbox). Our Service : Signal recomendation, Trading Course, P
consolidation faze before the breakout ? yeshas potential if 21 can break, can possibly enter here but at the risk of waiting a few months to a year for this trend channel to break to the upside, i prefer waiting for confirmation first! but we all have our own style. goodluck :)
TAK: ReversalIdea,
Inverse cup and handle.
Inverse head and shoulders
RSI divergence double bottom upward trend
top 18...
can it break ATH?
TAK - Takeda Pharma - TO THE MOON? - Major Covid 19 Discovery Researchers tout 'major scientifc discovery' in $14M study for COVID-19 treatment
www.cbc.ca
Close to 4,500 people participated in the study, lead researcher calls findings 'substantial' and 'robust'
CBC News · Posted: Jan 23, 2021 4:07 PM ET | Last Updated: January 23
The $14-million study was fu
TAK LongPossible inverse head and shoulders formation. ARK invest has been loading up shares. looking into June contracts or leaps.
TAKTAK is accumulating and it formed Inverse head and shoulders as well.
Also ARK is loading them in huge ... Get in the boat.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
TKPH5010047
Takeda Pharmaceutical Company Limited 3.175% 09-JUL-2050Yield to maturity
6.70%
Maturity date
Jul 9, 2050
TKPH5010048
Takeda Pharmaceutical Company Limited 3.375% 09-JUL-2060Yield to maturity
6.66%
Maturity date
Jul 9, 2060
TKPH5010046
Takeda Pharmaceutical Company Limited 3.025% 09-JUL-2040Yield to maturity
6.37%
Maturity date
Jul 9, 2040
TKPH5841810
Takeda Pharmaceutical Company Limited 5.8% 05-JUL-2064Yield to maturity
5.86%
Maturity date
Jul 5, 2064
TKPH5841809
Takeda Pharmaceutical Company Limited 5.65% 05-JUL-2054Yield to maturity
5.68%
Maturity date
Jul 5, 2054
TKPH5841808
Takeda Pharmaceutical Company Limited 5.65% 05-JUL-2044Yield to maturity
5.61%
Maturity date
Jul 5, 2044
TKPH5010045
Takeda Pharmaceutical Company Limited 2.05% 31-MAR-2030Yield to maturity
5.35%
Maturity date
Mar 31, 2030
TKPH5841807
Takeda Pharmaceutical Company Limited 5.3% 05-JUL-2034Yield to maturity
5.29%
Maturity date
Jul 5, 2034
TKPH4770188
Takeda Pharmaceutical Company Limited 5.0% 26-NOV-2028Yield to maturity
4.81%
Maturity date
Nov 26, 2028
Explore more bonds
Frequently Asked Questions
The current price of TKD is 25.26 EUR — it has decreased by −0.63% in the past 24 hours. Watch TAKEDA PHARMACEUTICAL CO LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange TAKEDA PHARMACEUTICAL CO LTD stocks are traded under the ticker TKD.
TKD stock has fallen by −1.37% compared to the previous week, the month change is a −3.33% fall, over the last year TAKEDA PHARMACEUTICAL CO LTD has showed a −1.52% decrease.
We've gathered analysts' opinions on TAKEDA PHARMACEUTICAL CO LTD future price: according to them, TKD price has a max estimate of 35.99 EUR and a min estimate of 25.62 EUR. Watch TKD chart and read a more detailed TAKEDA PHARMACEUTICAL CO LTD stock forecast: see what analysts think of TAKEDA PHARMACEUTICAL CO LTD and suggest that you do with its stocks.
TKD stock is 0.91% volatile and has beta coefficient of 0.47. Track TAKEDA PHARMACEUTICAL CO LTD stock price on the chart and check out the list of the most volatile stocks — is TAKEDA PHARMACEUTICAL CO LTD there?
Today TAKEDA PHARMACEUTICAL CO LTD has the market capitalization of 40.45 B, it has decreased by −0.30% over the last week.
Yes, you can track TAKEDA PHARMACEUTICAL CO LTD financials in yearly and quarterly reports right on TradingView.
TAKEDA PHARMACEUTICAL CO LTD is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
TKD earnings for the last quarter are 0.36 EUR per share, whereas the estimation was 0.23 EUR resulting in a 57.13% surprise. The estimated earnings for the next quarter are 0.20 EUR per share. See more details about TAKEDA PHARMACEUTICAL CO LTD earnings.
TAKEDA PHARMACEUTICAL CO LTD revenue for the last quarter amounts to 7.35 B EUR, despite the estimated figure of 6.80 B EUR. In the next quarter, revenue is expected to reach 6.99 B EUR.
TKD net income for the last quarter is 575.14 M EUR, while the quarter before that showed 552.39 M EUR of net income which accounts for 4.12% change. Track more TAKEDA PHARMACEUTICAL CO LTD financial stats to get the full picture.
TAKEDA PHARMACEUTICAL CO LTD dividend yield was 4.49% in 2023, and payout ratio reached 204.15%. The year before the numbers were 4.14% and 88.11% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 49.28 K employees. See our rating of the largest employees — is TAKEDA PHARMACEUTICAL CO LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TAKEDA PHARMACEUTICAL CO LTD EBITDA is 8.55 B EUR, and current EBITDA margin is 29.51%. See more stats in TAKEDA PHARMACEUTICAL CO LTD financial statements.
Like other stocks, TKD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAKEDA PHARMACEUTICAL CO LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TAKEDA PHARMACEUTICAL CO LTD technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TAKEDA PHARMACEUTICAL CO LTD stock shows the strong sell signal. See more of TAKEDA PHARMACEUTICAL CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.